glp-1 news today oct 2 2025 Understanding GLP-1s and their dynamic marketplace and workplace trends Can one drug do it

Wegovy and Zepbound: The Power Behind Our Program The medications Wegovy and Zepbound represent a major scientific breakthrough in the fight against obesity

Eli Lilly is planning to submit orforglipron (Foundayo) for the treatment of T2DM in the second quarter of 2026 under the CNPV pilot program, making it possible for the drug to receive FDA approval in late 2026

A Flexible Platform That Fits Your Schedule For busy professionals, convenience is key

Alcohol can reduce the drugs effectiveness and worsen side effects like drowsiness, confusion, or mood instability

The first question formulary decision-makers within plans must answer is, What will be the cost? PBMs have had challenges negotiating net prices for Wegovy that are equivalent to its sister product, Ozempic, for commercial payers

Some metabolically flexible individuals can maintain ketosis at up to 50 grams, but in the context of semaglutide-driven caloric restriction, erring toward the lower end is advisable